Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On March 3, 2017, the board of directors of AzurRx BioPharma,
Inc. (the Company) appointed Charles J. Casamento as a director.
Mr. Casamento, age 71, is currently Executive Director and
Principal of The Sage Group, a healthcare advisory group
specializing in mergers, acquisitions, and partnerships between
biotechnology companies and pharmaceutical companies, since 2007.
He was the president and CEO of Osteologix, Inc., a public
biopharmaceutical company developing products for treating
osteoporosis, from 2004 through 2007. From 1999 through 2004, he
served as chairman of the board, president and CEO of Questcor
Pharmaceuticals, Inc. which was subsequently acquired by
Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.s
president, CEO and chairman of the board from 1993 through 1999
until it merged with Cypros to form Questcor. He was co-founder,
president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus),
a biopharmaceutical company, from 1989 until 1993. Indevus was
eventually acquired by Endo. Mr. Casamento has also held senior
management positions at Genzyme Corporation, where he was senior
vice president, pharmaceuticals and biochemicals; American
Hospital Supply, where he was vice president of business
development and strategic planning for the Critical Care
Division; Johnson Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc.
Mr. Casamento also serves on the Board of Directors of Relmada
Therapeutics, Inc. and International Stem Cell Corporation. He is
Chairman of the Audit Committee at Relmada.

During his career, he has sat on the boards of ten public
companies and has also been a Director and Vice Chairman of The
Catholic Medical Missions Board, a large not for profit
organization providing health care services to third world
countries. He has served as a guest lecturer at Fordham
University and is on the Science Council of Fordham University.
He holds a bachelors degree in Pharmacy from Fordham University
and an M.B.A. from Iona College. We believe that Mr. Casamentos
qualifications to serve on our Board include his significant
experience as chief executive officer in various life sciences
companies and his service on several other boards, which bring
valuable knowledge and insights to our board.

There have been no transactions in the past two years to which
the Company or any of its subsidiaries was or is to be a party,
in which Mr. Casamento had, or will have, a direct or indirect
material interest.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated March 8, 2017.